Investor Relations
Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Acceptance of the Application for Marketing Authorization for the New Indication of Triptorelin Acetate Microspheres for Injection
Time：2023-08-24
Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 Second Extraordinary General Meeting
Time：2023-08-23
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resignation of Independent Director and By-election of Independent Director
Time：2023-08-23
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Approval for Registration of Blonanserin Tablets
Time：2023-08-11
Ad hoc announcement pursuant to Art. 53 LR-JCARE Supplemental Announcement on the Livzon Group Entering into the Patent and Technology Transfer Agreement
Time：2023-07-21
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Livzon Group Entering into The Patent and Technology Transfer Agreement
Time：2023-07-20
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Approval of Drug Clinical Trials for Recombinant SARS-COV-2 Bivalent (Original/Omicron XBB) Fusion Protein Vaccine (CHO Cell)
Time：2023-07-14
Ad hoc announcement pursuant to Art. 53 LR-Announcement on the Implementation of 2022 Profit Distribution of JCARE
Time：2023-07-13
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Obtaining the Drug Registration Certificate
Time：2023-07-11
Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Cancellation of the Treasury Shares Previously Repurchased
Time：2023-07-03
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.